Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
AbbVie Corp a un objectif de cours consensuel de 567,61 $ basé sur les notes de 38 analystes. Le plus haut est de 1 350 $ émis par HSBC le 10 mai 2024<. Le plus bas est de 100 $ émis par Deutsche Bank le 5 août 2024. Les 3 dernières notations d'analystes ont été publiées par New Street Research, Goldman Sachs et Deutsche Bank respectivement le 6 août 2024, le 5 août 2024 et le 5 août 2024. Avec un objectif de cours moyen de 118,33 $ entre New Street Research, Goldman Sachs et Deutsche Bank, il existe une hausse implicite de 0,21 % pour AbbVie Corp à partir de ces notations d'analystes les plus récentes.
Sociétés d'analyse émettant des recommandations1
Piper Sandler
B of A Securities
Evercore ISI Group
Berenberg
JP Morgan
1calculé à partir des notes des analystes
Notes d'analystes pour AbbVie
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/10/2025 | — | Piper Sandler | $231 → $284 | Maintains | Overweight | |||
10/03/2025 | — | B of A Securities | $220 → $251 | Maintains | Neutral | |||
10/01/2025 | — | HSBC | — | Downgrade | Buy → Hold | |||
09/22/2025 | — | Evercore ISI Group | $207 → $222 | Maintains | Outperform | |||
09/17/2025 | — | Berenberg | $170 → $270 | Upgrade | Hold → Buy | |||
09/16/2025 | — | JP Morgan | $200 → $235 | Maintains | Overweight | |||
09/15/2025 | — | Cantor Fitzgerald | $215 → $245 | Maintains | Overweight | |||
09/12/2025 | — | Wells Fargo | $240 → $260 | Maintains | Overweight | |||
09/12/2025 | — | BMO Capital | $215 → $240 | Maintains | Outperform | |||
08/12/2025 | — | Piper Sandler | → $231 | Assumes | → Overweight | |||
08/01/2025 | — | Evercore ISI Group | $205 → $207 | Maintains | Outperform | |||
08/01/2025 | — | Guggenheim | $216 → $227 | Maintains | Buy | |||
08/01/2025 | — | Morgan Stanley | $250 → $255 | Maintains | Overweight | |||
08/01/2025 | — | Raymond James | $227 → $236 | Maintains | Outperform | |||
05/14/2025 | — | Citigroup | $210 → $205 | Downgrade | Buy → Neutral | |||
04/29/2025 | — | Guggenheim | $214 → $216 | Maintains | Buy | |||
04/28/2025 | — | B of A Securities | $200 → $204 | Maintains | Neutral | |||
04/28/2025 | — | Raymond James | $220 → $227 | Maintains | Outperform | |||
04/28/2025 | — | Evercore ISI Group | $204 → $205 | Maintains | Outperform | |||
04/28/2025 | — | Morgan Stanley | $241 → $250 | Maintains | Overweight | |||
04/22/2025 | — | Cantor Fitzgerald | → $210 | Initiates | → Overweight | |||
04/21/2025 | — | B of A Securities | $223 → $200 | Maintains | Neutral | |||
04/17/2025 | — | Guggenheim | $214 → $214 | Reiterates | Buy → Buy | |||
04/11/2025 | — | Citigroup | $215 → $210 | Maintains | Buy | |||
04/09/2025 | — | Morgan Stanley | $239 → $241 | Maintains | Overweight | |||
04/08/2025 | — | Goldman Sachs | → $194 | Assumes | → Neutral | |||
03/05/2025 | — | Wells Fargo | $210 → $240 | Maintains | Overweight | |||
03/04/2025 | — | B of A Securities | $200 → $223 | Maintains | Neutral | |||
02/03/2025 | — | Citigroup | $205 → $215 | Maintains | Buy | |||
02/03/2025 | — | Truist Securities | $211 → $217 | Maintains | Buy | |||
02/03/2025 | — | UBS | $181 → $190 | Maintains | Neutral | |||
02/03/2025 | — | Wells Fargo | $195 → $210 | Maintains | Overweight | |||
02/03/2025 | — | Morgan Stanley | $224 → $239 | Maintains | Overweight | |||
02/03/2025 | — | Raymond James | $218 → $220 | Reiterates | Outperform → Outperform | |||
02/03/2025 | — | Guggenheim | $212 → $214 | Maintains | Buy | |||
02/03/2025 | — | BMO Capital | $208 → $215 | Maintains | Outperform | |||
01/28/2025 | — | Citigroup | $215 → $205 | Maintains | Buy | |||
01/27/2025 | — | Piper Sandler | $220 → $227 | Maintains | Overweight | |||
01/17/2025 | — | Guggenheim | $221 → $212 | Maintains | Buy | |||
01/08/2025 | — | Truist Securities | $215 → $211 | Maintains | Buy | |||
12/17/2024 | — | Piper Sandler | $212 → $220 | Maintains | Overweight | |||
12/10/2024 | — | B of A Securities | → $191 | Reinstates | → Neutral | |||
11/22/2024 | — | Leerink Partners | → $206 | Upgrade | Market Perform → Outperform | |||
11/18/2024 | — | Wells Fargo | $205 → $195 | Maintains | Overweight | |||
11/15/2024 | — | Wolfe Research | → $205 | Initiates | → Outperform | |||
11/13/2024 | — | JP Morgan | $210 → $200 | Maintains | Overweight | |||
11/12/2024 | — | UBS | $200 → $181 | Maintains | Neutral | |||
11/12/2024 | — | Citigroup | $226 → $215 | Maintains | Buy | |||
11/12/2024 | — | BMO Capital | $228 → $208 | Maintains | Outperform | |||
11/12/2024 | — | Morgan Stanley | $231 → $224 | Maintains | Overweight | |||
11/06/2024 | — | Guggenheim | $212 → $221 | Maintains | Buy | |||
11/04/2024 | — | Argus Research | — | Upgrade | Hold → Buy | |||
10/31/2024 | — | Cantor Fitzgerald | $200 → $240 | Maintains | Overweight | |||
10/31/2024 | — | B of A Securities | $195 → $210 | Maintains | Neutral | |||
10/31/2024 | — | BMO Capital | $220 → $228 | Maintains | Outperform | |||
10/31/2024 | — | Citigroup | $215 → $226 | Maintains | Buy | |||
10/31/2024 | — | UBS | $195 → $200 | Maintains | Neutral | |||
10/31/2024 | — | Morgan Stanley | $218 → $231 | Maintains | Overweight | |||
10/25/2024 | — | Citigroup | $170 → $215 | Maintains | Buy | |||
10/18/2024 | — | B of A Securities | $185 → $195 | Maintains | Neutral | |||
10/17/2024 | — | BMO Capital | $214 → $220 | Maintains | Outperform | |||
10/17/2024 | — | Bernstein | → $203 | Initiates | → Market Perform | |||
10/10/2024 | — | Truist Securities | $210 → $215 | Maintains | Buy | |||
10/09/2024 | — | UBS | $185 → $195 | Maintains | Neutral | |||
10/07/2024 | — | Barclays | $200 → $212 | Maintains | Overweight | |||
10/07/2024 | — | TD Cowen | $195 → $225 | Maintains | Buy | |||
08/23/2024 | — | Piper Sandler | $196 → $209 | Maintains | Overweight | |||
08/12/2024 | — | Morgan Stanley | $211 → $218 | Maintains | Overweight | |||
08/05/2024 | — | Cantor Fitzgerald | $200 → $200 | Reiterates | Overweight → Overweight | |||
07/26/2024 | — | UBS | $172 → $185 | Maintains | Neutral | |||
07/26/2024 | — | Cantor Fitzgerald | $200 → $200 | Reiterates | Overweight → Overweight | |||
07/26/2024 | — | Truist Securities | $195 → $210 | Reiterates | Buy → Buy | |||
07/26/2024 | — | Wells Fargo | $200 → $205 | Maintains | Overweight | |||
07/26/2024 | — | Barclays | $187 → $200 | Maintains | Overweight | |||
07/25/2024 | — | JP Morgan | $190 → $210 | Maintains | Overweight | |||
07/19/2024 | — | BMO Capital | $180 → $214 | Maintains | Outperform | |||
07/11/2024 | — | Morgan Stanley | $191 → $196 | Maintains | Overweight | |||
07/09/2024 | — | Cantor Fitzgerald | $200 → $200 | Reiterates | Overweight → Overweight | |||
07/02/2024 | — | Piper Sandler | $190 → $190 | Maintains | Overweight | |||
06/20/2024 | — | Cantor Fitzgerald | $200 → $200 | Reiterates | Overweight → Overweight | |||
06/18/2024 | — | Piper Sandler | $185 → $190 | Maintains | Overweight | |||
06/05/2024 | — | HSBC | → $185 | Upgrade | Hold → Buy | |||
05/17/2024 | — | Cantor Fitzgerald | → $200 | Initiates | → Overweight | |||
04/29/2024 | — | Morgan Stanley | $196 → $191 | Maintains | Overweight | |||
04/29/2024 | — | Barclays | $195 → $187 | Maintains | Overweight | |||
04/29/2024 | — | BMO Capital | $195 → $180 | Maintains | Outperform | |||
03/27/2024 | — | Barclays | $185 → $195 | Maintains | Overweight | |||
03/22/2024 | — | Guggenheim | $188 → $190 | Maintains | Buy | |||
02/06/2024 | — | UBS | $165 → $172 | Maintains | Neutral | |||
02/06/2024 | — | Raymond James | $181 → $189 | Maintains | Outperform | |||
02/06/2024 | — | Truist Securities | $180 → $195 | Maintains | Buy | |||
02/05/2024 | — | Wells Fargo | $180 → $200 | Maintains | Overweight | |||
02/05/2024 | — | Raymond James | $181 → $189 | Maintains | Outperform | |||
02/05/2024 | — | BMO Capital | $187 → $195 | Maintains | Outperform | |||
02/05/2024 | — | Barclays | $175 → $185 | Maintains | Overweight | |||
01/29/2024 | — | William Blair | — | Upgrade | Market Perform → Outperform | |||
01/23/2024 | — | Barclays | $170 → $175 | Maintains | Overweight | |||
01/02/2024 | — | Wells Fargo | $195 → $180 | Maintains | Overweight | |||
12/18/2023 | — | HSBC | $167 → $156 | Downgrade | Buy → Hold | |||
12/11/2023 | — | Goldman Sachs | → $173 | Upgrade | Neutral → Buy |
FAQ
Quel est le cours indicatif de l'action AbbVie (ABBV) ?
Le dernier objectif de prix pour AbbVie (NYSE:ABBV) a été rapporté par Piper Sandler le octobre 10, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $284.00 s'attendant à ce que ABBV se rise dans les 12 prochains mois (un possible changement de 23.82% upside). 62 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour AbbVie (ABBV) ?
La dernière note d'analyste pour AbbVie (NYSE:ABBV) a été fournie par Piper Sandler, et AbbVie maintenu leur note overweight.
Quand a eu lieu la dernière mise à niveau pour AbbVie (ABBV) ?
La dernière amélioration pour AbbVie Inc a eu lieu le septembre 17, 2025 lorsque Berenberg a augmenté leur objectif de prix à $270. Berenberg avait précédemment a hold pour AbbVie Inc.
Quand a eu lieu la dernière dégradation pour AbbVie (ABBV) ?
La dernière réduction pour AbbVie Inc a eu lieu le octobre 1, 2025 lorsque HSBC a changé leur objectif de prix de N/A à N/A pour AbbVie Inc.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour AbbVie (ABBV) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de AbbVie, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour AbbVie a été déposée le octobre 10, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers octobre 10, 2026.
La note d'analyste pour AbbVie (ABBV) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de AbbVie (ABBV) était un maintenu avec un objectif de prix de $231.00 à $284.00. Le prix actuel de AbbVie (ABBV) est de $229.37, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.